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ABSTRACT 
Strayer, Kraig Edward. M.S. Department of Chemistry, Wright State University, 2018. A 
LC-MS/MS-Based Method for the Multiplex Detection of 24 Fentanyl Analogs and 
Metabolites in Whole Blood at Sub ng mL-1 Concentrations 
 
The United States and numerous other countries worldwide are currently experiencing a 
public health crisis due to the abuse of illicitly manufactured fentanyl (IMF) and its 
analogues. This manuscript describes the development of a liquid chromatography-
tandem mass spectrometry-based method for the multiplex detection of N = 24 IMF 
analogues and metabolites in whole blood at concentrations as low as 0.1−0.5 ng mL−1. 
These available IMFs were fentanyl, norfentanyl, furanyl norfentanyl, remifentanil acid, 
butyryl norfentanyl, remifentanil, acetyl fentanyl, alfentanil, AH-7921, U-47700, acetyl 
fentanyl 4-methylphenethyl, acrylfentanyl, para-methoxyfentanyl, despropionyl fentanyl 
(4-ANPP), furanyl fentanyl, despropionyl para-fluorofentanyl, carfentanil, (±)-cis-3-
methyl fentanyl, butyryl fentanyl, isobutyryl fentanyl, sufentanil, valeryl fentanyl, para-
fluorobutyryl fentanyl, and para-fluoroisobutyryl fentanyl. Most IMF analogues (N = 22) 
could be easily distinguished from one another; the isomeric forms butyryl/isobutyryl 
fentanyl and para-fluorobutyryl/para-fluoroisobutyryl fentanyl could not be 
differentiated. N = 13 of these IMF analogues were quantified for illustrative purposes, 
and their forensic quality control standards were also validated for limit of detection 
(0.017−0.056 ng mL−1), limit of quantitation (0.100−0.500 ng mL−1), 
selectivity/sensitivity, ionization suppression/enhancement (87−118%), process 
v 
 
efficiency (60−95%), recovery (64−97%), bias (<20%), and precision (>80%). This 
flexible, time- and cost-efficient method was successfully implemented at the 
Montgomery County Coroner’s Office/Miami Valley Regional Crime Laboratory in 
Dayton, Ohio, where it aided in the analysis of N = 725 postmortem blood samples 
collected from February 2015 to November 2016.   
vi 
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1. Introduction 
 
Fentanyl is a synthetic opioid that was developed for pharmaceutical use in 1960 by 
Paul Janssen in Belgium.1−4 Since its introduction into the United States in 1970, fentanyl 
has rapidly become a leading analgesic and anesthetic agent due to its 50−100 times 
higher potency than that of morphine, shorter onset, and quicker absorption by the human 
body.3,4 Fentanyl causes depression of the respiratory and central nervous system in a 
dose-dependent manner. Over the past few years, increased availability and abuse of 
illicitly manufactured fentanyl (IMF) and its analogues emerged as a significant threat to 
public health in the United States and other countries.5−10 Ohio is one of several U.S. 
states that was gravely impacted by the opioid epidemic; the number of IMF-related 
overdose deaths increased by 526% between 2013 and 2015.11 Even more alarming is the 
fact that new IMF analogues are being synthesized in Asian countries and marketed on a 
regular basis across United States and Europe in an attempt to stay ahead of 
regulations.12−14 Many of these analogues have increased potency compared with IMF. 
For example, carfentanil or the so called “elephant tranquilizer” entered the U.S. market 
in July 2016 and is known to be 100 times more potent than fentanyl.15,16 From July to 
November 2016, over 80% of all carfentanil positive cases in the United States (i.e., N = 
451 cases) were reported in Ohio.17  
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The U.S. Drug Enforcement Agency (DEA) has responded to this epidemic by 
declaring IMF a public health safety factor on March 18th, 2015.8 Unfortunately, IMF 
and its analogues are not always part of routine toxicology testing in the United States. 
Thus, there is an urgent need for developing sensitive, multiplex detection methods that 
could be easily modified to include newly emerging IMF analogues. A successful method 
was reported in 2017 by the Miami-Dade County Medical Examiner Department, where 
an ultrahigh performance liquid chromatography ion trap mass spectrometry system with 
MSn capabilities (UHPLC-Ion-Trap-MSn) was employed for the qualitative 
identification of N = 13 IMF analogues (i.e., acetyl fentanyl, alfentanil, β-
hydroxythiofentanyl, butyryl fentanyl, carfentanil, despropionyl fentanyl, fentanyl, 
furanyl fentanyl, norfentanyl, 4-fluoroisobutyryl fentanyl, 4-fluorobutyryl fentanyl, 
sufentanil, and U-47700) in postmortem samples.18  
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Figure 1. Molecular structure of N = 24 IMF analogues, metabolites, and synthetic opioids used for the development 
of the LC-MS/MS-based method. 
The Key Aim of this study is to describe the development and validation of a new 
liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based method for the 
multiplex detection of N = 24 IMF analogues, metabolites, and synthetic opioids. The 
IMF analogues were selected on the basis of previous forensic reports and their presence 
on the Dark Web:19 (1) norfentanyl, (2) furanyl norfentanyl, (3) remifentanil acid, (4) 
butyryl norfentanyl, (5) remifentanil, (6) acetyl fentanyl, (7) alfentanil, (8) AH-7921, (9) 
U-47700, (10) acetyl fentanyl 4-methylphenethyl, (11) acrylfentanyl, (12) fentanyl, (13) 
para-methoxyfentanyl, (14) despropionyl fentanyl (4-ANPP), (15) furanyl fentanyl, (16) 
despropionyl para-fluorofentanyl, (17) carfentanil, (18) (±)-cis-3-methyl fentanyl, (19) 
butyryl fentanyl, (20) isobutyryl fentanyl, (21) para-fluorobutyryl fentanyl, and (22) para-
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fluoroisobutyryl fentanyl, (23) sufentanil, and (24) valeryl fentanyl (Figure 1). U-47700 
is not an analogue of fentanyl and is not approved as a pharmaceutical agent, but it is 
typically included in fentanyl studies because of its similar, potent analgesic activity and 
combination with IMF in cases of overdose deaths.20 AH-7921 is also a synthetic opioid 
analgesic that was placed into schedule I of the U.S. Controlled Substances Act in 2016.21 
It is usually incorporated in fentanyl-related studies due to its structure being similar to 
that of IMF and potency comparable to that of morphine.22  
In this study, LC-MS/MS is the analytical method of choice because of its 
common use in numerous forensic and toxicology laboratories across the nation.23 LC has 
become the leading separation technique in chromatography due to its flexibility, 
reproducibility, and efficiency. Although LC achieves the physical separation of multiple 
components in a mixture, MS offers information about their structural identity. The 
addition of tandem MS technology further improves the specificity and accuracy of the 
detection method. The triple-quadrupole mass spectrometry (QQQ) capability of the 
selected system facilitates the simultaneous identification and quantification of fentanyl 
analogues. QQQ performs a true multiple-reaction monitoring (MRM) mode scan 
because both mass analyzers can simultaneously monitor quantitative and qualitative ion 
transitions. Running dynamic MRM24,25 is desired for rapid and simple quantifications 
due to its dynamic/noble range and sensitivity.26 Pairing LC-MS/MS with solid phase 
extraction (SPE)27 allows for the identification and quantification of IMF analogues from 
postmortem blood. 
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2. Methods 
2.1 Materials.  
High-performance liquid chromatography (HPLC) grade water and acetonitrile 
(ACN) were purchased from Honeywell (Morris Plains, NJ). Formic acid (88%), 
methanol, ammonium formate, potassium phosphate mono-basic-sodium hydroxide 
buffer solution (phosphate-buffered saline (PBS), pH 6.0), glacial acetic acid, ammonium 
hydroxide, isopropanol, and methylene chloride were obtained from Fisher Scientific 
(Pittsburgh, PA). Certified reference standards of acetyl fentanyl, acetyl norfentanyl, 
alfentanil, sufentanil, fentanyl, and norfentanyl were acquired from both Cerilliant 
(Round Rock, TX) and Lipomed (Cambridge, MA). Butyryl fentanyl and (±)-cis-3-
methyl fentanyl were procured from both Lipomed and Cayman Chemical. Butyryl 
norfentanyl, para-fluorofentanyl, para-fluorobutyryl fentanyl, furanyl fentanyl, furanyl 
norfentanyl, valeryl fentanyl, acrylfentanyl, isobutyryl fentanyl, despropionyl para-
fluorofentanyl, 4-ANPP, U-47700, 4-fluoroisobutyryl fentanyl, para-methoxyfentanyl, 
acetyl fentanyl 4-methylphenethyl analogue, and AH-7921 were purchased from Cayman 
Chemical (Ann Arbor, MI). Remifentanil and remifentanil metabolite were obtained from 
Cerilliant. Internal standards were acetyl fentanyl-13C6, fentanyl-d5, and norfentanyl-d5 
from Cerilliant. Carfentanil was donated by DEA. Clean screen drugs of abuse (DAU) 
SPE columns were acquired from United Chemical Technologies Worldwide Monitoring 
(Bristol, PA).  
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2.2 Instrumentation.  
Two different LC-MS/MS systems (Agilent Technologies, Santa Clara, CA) were 
employed for validation purposes: (1) a 1200 series LC system (Binary HPLC Pump, 
high-performance autosampler, and vacuum degasser) equipped with a 6410 triple 
quadrupole, and (2) an HPLC 1260 Infinity system (binary pumps, a six-port valve, and 
high-performance autosampler) coupled to a 6420 triple quadrupole HPLC-MS/MS 
system.  
   
Figure 2. Left: Image of a 1200 series LC system coupled with a 6410 triple quadrupole. Right: Image of an HPLC 1260 
Infinity system coupled to a 6420 triple quadrupole (reproduced with permission of the Montgomery County 
Coroner’s Office laboratories). 
 
The analytical column on both instruments was a Raptor biphenyl LC column (150.0 mm 
x 3.0 mm, 2.7 μm) that was purchased from Restek (Bellefonte, PA). SPE was done on a 
UCT Positive Pressure Manifold.  
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Figure 3. Image of a UCT Positive Pressure Manifold used for extractions (reproduced with permission of the 
Montgomery County Coroner’s Office laboratories). 
 
2.3 Preparation of Calibration and Quality Control Solutions. 
Stock standards and stock controls of 1 and 100 ng mL−1 were prepared for all 
IMF analogues by dilution of the purchased certified reference material in methanol and 
were stored at −4 °C for up to 3 months. All standards (0.1−50.0 ng mL−1) and quality 
controls (0.35, 2.5, and 25.0 ng mL−1) were made by serial dilution from stocks directly 
into treated blank whole blood (see Biological Matrices). The quality control 
concentrations were selected to fit the low (quality control low concentration (QCLO)), 
medium (medium concentration (QCMED)), and high (high concentration (QCHI)) ends 
of the calibration range. Additional controls included blank water and blank whole blood. 
All standards and quality controls excluding blank water were spiked with three internal 
standards to a final concentration of 10.0 ng mL−1. The norfentanyl-d5 (stock of 100.0 
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μg mL−1), fentanyl-d5 (100.0 μg mL
−1), and acetyl fentanyl-13C6 (50.0 μg mL
−1) 
working internal standards were prepared by 5−10-fold volumetric dilution of stock 
internal standard to 100.0 ng mL−1 in methanol. 2H1 and 
13C6 internal standards were 
selected for use due to their structural similarity and physicochemical properties 
compared to those of the IMFs. Fentanyl-d5 was used as the internal standard for all IMF 
analogues without a stable, labeled internal standard on the market due to the limited 
availability of most analogues and the structural similarities to fentanyl. Controls 
(triplicate) and calibration standards were extracted daily. Post extraction controls (spiked 
after separation) and neat controls (directly evaporated and not extracted) were also made 
for method validation purposes.  
2.4 Biological Matrices. 
Whole blood free of pathogens was obtained from the Community Blood Center, 
Dayton, OH. Blank whole blood was preserved with sodium fluoride (1%) and was 
refrigerated (∼4 °C) or frozen (−10 to −20°C). Before use, the acquired blood was 
analyzed for over 70 potential contaminants and drugs of abuse (Table S1) by running a 
blank sample through multiple extractions and quantifications. Verified whole blood was 
diluted with water at a 1:1 ratio. Because of limited blood supply, the product was diluted 
to extend the amount of blood needed for each analysis; however, proficiency blind tests 
were carried out to demonstrate accurate analyte quantitation for accreditation purposes.  
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2.5 Sample Preparation and Solid Phase Extraction.  
Calibrants, controls, and samples were treated the same throughout all 
experiments for method validation. Briefly, 1.0 mL of whole blood was added to 4.0 mL 
of PBS and 2.0 mL of water in a 16 x 125 Pyrex Screw Cap Tube. Each sample was then 
spiked with 100.0 μL of internal standard. Calibrators and controls were administered to 
additional stock solutions, resulting in seven calibration concentrations (0.1, 0.25, 0.5, 
1.0, 5.0, 10.0, and 50.0 ng mL−1) and three quality controls (0.35, 2.5, and 25.0 ng 
mL−1). Afterward, calibrants, controls, and samples were vortexed and centrifuged at 
3000 rpm (1811g) for 10 min to remove particulate matter prior to SPE.  
The isolation of IMFs was selectively achieved using CLEAN SCREEN DAU 
columns (United Chemical Technologies Bristol, PA). Desired drugs were selectively 
eluted by maintaining the pH of reagents and column close to 6.0 through the addition of 
PBS buffer. Briefly, SPE columns were preconditioned and activated with 3.0 mL of 
methanol, washed with 3.0 mL of water, and conditioned to pH 6.0 with PBS. Slight 
positive pressure (∼10 psi) was employed for each wash using a UCT Positive Pressure 
Manifold.  
Calibrants, controls, and samples were loaded into the SPE columns, which were 
then washed with 3.0 mL of water, 1.0 mL of 1.0 M of acetic acid, and 3.0 mL of 
methanol to remove potential interferences. The cationic IMFs were eluted with 3.0 mL 
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of a v/v/v methylene chloride/isopropanol/ammonium hydroxide mixture (78:20:2). The 
eluate was collected and evaporated at 40 °C under a stream of air. Analytes were then 
reconstituted with 100.0 μL of methanol and injected into LC-MS/MS.  
2.6 Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS).  
Separation of fentanyl analytes was achieved with a Raptor biphenyl analytical 
column heated to 40 °C. Mobile phase A (MPA) consisted of 10.0 mM ammonium 
formate and 0.1% formic acid in water. Mobile phase B (MPB) was made of 0.1% formic 
acid in ACN. MPA and MPB were held for 2 min at 90/10%. MPA was gradually ramped 
down from 90 to 10% over 6 min, then held for 0.5 min at 10/90%, and finally returned 
to 90/10% in 0.1 min, and was held for the remainder of the time. A total run time of 13.5 
min ensured the elution of analytes and the equilibration of the column.  
Electrospray ionization in a positive ion scan mode was selected for MS 
measurements. Source parameters were maintained for nitrogen gas temperature (350 
°C), gas flow (12.0 L min−1), and capillary voltage (4000 V). Detection was 
accomplished by using a dynamic MRM scan function. Precursor and product ions were 
identified using the Optimizer software (Agilent) and manual determination (Table 1). 
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Table 1. Precursor ions along with their qualitative and quantitative transitions for all IMF analogs (N = 24) and internal standards (N = 3, in bold). 
Peak Analyte 
Quant 
Transition (m/z) 
Qualifier Transitions 
(m/z) 
Fragmentor (V) Collision Energy (V) 
1 
Norfentanyl-d5 238.4-84.1 238.4-55.2 106 16, 44 
2 
Norfentanyl 233.4-84.1 233.4-94.0, 233.4-55.2 106 16, 36, 44 
3 
Furanyl norfentanyl 271.4-84.1 271.4-95.0 106 16, 44 
4 
Remifentanil acid 363.4-53.2 363.4-81.1 111 72, 44 
5 
Butyryl norfentanyl 247.3-84.1 247.3-94.0, 247.3-55.2 106 16, 32, 44 
6 
Remifentanil 377.5-317.0 377.5-345.0 25 15 
7 
Acetyl fentanyl 323.0-105.0 323.0-188.0 141 20, 40 
8 
Acetyl Fentanyl 13C6 329.4-105.0 329.4-77.1 136 44, 96 
9 
Alfentanil 417.5-165.0 417.5-99.0, 417.5-77.1 131 36, 40, 100 
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14 
AH-7921 329.0-95.1 329.0-284.0 111 20, 36 
10 
U-47700 329.0-81.0 329.0-204.0 120 36, 25 
11 
Acetyl fentanyl 4-methylphenethyl 337.5-119.0 337.5-91.1 136 36, 72 
12 
Acrylfentanyl 335.5-105.0 335.5-77.1, 335.5-51.2 141 44, 92, 140 
15 
Fentanyl-d5 342.5-105.0 342.5-77.1 141 44, 100 
13 
Fentanyl 337.5-188.0 337.5-105.0 131 20, 44 
17 
para-Methoxyfentanyl 367.6-105.0 367.6-77.1, 367.6-51.2 136 44, 108, 160 
16 
4-ANPP 281.4-105.1 284.4-77.2, 281.4-51.3 116 36, 76, 124 
18 
Furanyl fentanyl 375.1-105.0 375.1-188.2 125 40, 25 
19 
Despropionyl para-Fluorofentanyl 299.4-105.0 299.4-77.1, 299.4-51.2 111 36, 88, 88 
22 
Carfentanil 395.2-113.0 395.2-105.0, 395.2-77.1 131 36, 56, 112 
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20 
()-cis-3-Methyl fentanyl 351.5-202.1 351.5-105.0 150 20, 48 
21 
Butyryl/Isobutyryl fentanyl 351.2-188.1 351.2-105.1 146 24, 48 
23 para-Fluorobutyryl/para-
Fluoroisobutyryl fentanyl 
369.2-105.1 369.2-188.1, 369.2-77.1 141 44, 24, 108 
24 
Sufentanil 387.6-111.0 387.3-238.2, 387.6-132.0 121 44, 36, 36 
25 
Valeryl fentanyl 365.5-105.0 365.5-77.1, 365.5-51.2 136 44, 112, 164 
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2.7 LC-MS/MS Assay Validation.  
Validation followed method development and occurred daily over 5 days. It 
included a batch of seven calibrators, controls in triplicate, a negative blood blank, and a 
water blank. The limit of detection (LOD), limit of quantitation (LOQ), bias, precision 
(coefficient of variation, % CV), linearity, matrix effects, recovery, carryover, and any 
potential interferences were determined within the validation period.  
2.8 Data Analysis.  
The software used for data analysis was MassHunter Qualitative and Quantitative 
analysis. Data was plotted in Excel 2016 and Origin 8 software. The development of the 
LC-MS/MS method required the adaptation of the following: (1) SPE extractions for 
separation of the analytes of interest from interferences inherent in biological matrices, 
(2) LC for further improvement in sensitivity and specificity, and (3) MS/MS for MRM 
transitions specific to each IMF analogue and analogue quantification at sub ng mL−1 
concentrations.  
SPE Extractions were performed according to the United Chemical Technologies 
extraction method (10.5)26 for N = 9 IMF analogues in urine (fentanyl, alfentanil, 
carfentanil, sufentanil, 3-methyl fentanyl, para-fluorofentanyl, α-methyl fentanyl, 
thianfentanil, and lofentanil). This gas chromatography−mass spectrometry (GC−MS) 
method was successfully adapted for the extraction of all N = 24 IMF analogues in whole 
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blood specimens.  
2.9 LC Optimization.  
First, two columns were tested: C-18 and biphenyl. The C-18 column proved 
inefficient for the separation of all IMF analogues, whereas the biphenyl column was 
found to generate an improved signal-to-noise ratio and separation. Thus, the biphenyl 
column was selected for method validation. Three mobile phase mixtures (methanol and 
formic acid, ammonium formate and formic acid in water (MPA), and formic acid in 
ACN (MPB)) were explored to provide the best separation of IMF analogues in the 
shortest amount of time.  
Exploratory work deemed methanol and formic acid as unsuitable because 
separation of IMF analogues could not be achieved within acceptable time frames (<20 
min) and corresponding chromatography exhibited poor signal-to-noise ratios under the 
studied conditions. Following this, MPA and MPB mixtures were deemed acceptable for 
a gradient method by achieving time efficient separation (13.5 min). A flow rate of 0.400 
mL min−1 was selected to accommodate the maximum column pressure on both LC-
MS/MS systems. The gradient change of mobile phases was then optimized from 90% 
MPA/ 10% MPB to 10% MPA/90% MPB to achieve a total run time of 13.5 min per 
sample (Figure S1).  
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2.10 MS/MS Optimization. 
Electrospray ionization mode paired with tandem quadrupole mass spectrometry 
was employed for MRM transitions, which were optimized for high sensitivity of each 
IMF analogue. Briefly, precursor-ion and product-ion transitions for each IMF analogue 
and internal standards (Table 1) were mostly determined using the Agilent Optimizer 
software. Manual adjustment of the fragmentor and collision energy voltage was done 
when the software adjustment led to low sensitivity for the qualifier transitions ((±)-cis-3-
methyl fentanyl, U-47700, and remifentanil). MRM transitions were identified by the 
highest sensitivity and specific discrimination between coeluting analogues (e.g., AH-
7921 and U-47700 in Table 1). Separation and identification between butyryl fentanyl 
and isobutyryl fentanyl and para-fluorobutyryl fentanyl and 4-fluoroisobutyryl fentanyl 
could not be achieved under current conditions. Thus, they were classified as butyryl/ 
isobutyryl and para-fluoroisobutyryl fentanyl/para-fluorobutyryl fentanyl. Using this 
method, the isomeric IMF analogues can be detected but not distinguished from each 
other. Thus, Figure 2 shows only the quantitative transitions of N = 22 fentanyl analogues 
and N = 3 internal standards. The acquisition method report is provided in the Supporting 
Information.  
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Figure 4. LC-MS/MS ion chromatogram of a high calibrator. Each peak represents the quantitative transition ion (qualitative transition ion not shown). 
Fentanyl analogue and internal standard peak identities: (1) norfentanyl-d5, (2) norfentanyl, (3) furanyl norfentanyl, (4) remifentanil acid, (5) butyryl 
norfentanyl, (6) remifentanil, (7) acetyl fentanyl, (8) acetyl fentanyl-
13
C6, (9) alfentanil, (10) U-47700, (11) acetyl fentanyl 4-methylphenethyl, (12) 
acrylfentanyl, (13) fentanyl, (14) AH-7921, (15) fentanyl-d5, (16) 4-ANPP, (17) para-methoxyfentanyl, (18) furanyl fentanyl, (19) despropionyl para-
fluorofentanyl, (20) (±)-cis-3-methyl fentanyl, (21) butyryl/isobutyryl fentanyl, (22) carfentanil, (23) para-fluorobutyryl/ para-fluoroisobutyryl fentanyl, (24) 
sufentanil, and (25) valeryl fentanyl. Separation between butyryl/isobutyryl and para-fluoroisobutyryl fentanyl/ para-fluorobutyryl fentanyl was not achieved 
due to isomerism. 
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2.11 Method Validation.  
The directed assay was validated by determining the limit of detection (LOD), 
limit of quantitation (LOQ), selectivity and specificity, recovery, ion suppression/ 
enhancement, process efficiency, bias, and precision. All analyses were performed after a 
5 day validation period. LOD, lower limit of quantitation (LLOQ), upper limit of 
quantitation, bias, and precision were calculated over five replicates from five 
consecutive days.  
2.12 Limit of Detection (LOD).  
LODs for IMF analogues are listed in Table 2. Evaluation of LOD for most IMF 
analogues (excluding fentanyl) was carried out by using a linear calibration curve model. 
LOD was estimated using eq. 1  
𝐿𝑂𝐷 =
3.3 𝑠𝑦
𝐴𝑣𝑔𝑚                                                                 
(1) 
where sy is the standard deviation of the y-intercept and Avgm is the average of the 
calibration slopes.  
LOD of fentanyl (quadratic fit, 1/x) was determined by evaluating the calibration 
standards 1/2, 1/5, and 1/10 of the lowest calibrator (i.e., 0.05, 0.025, and 0.01 ng mL−1) 
for the lowest fentanyl concentration with an acceptable signal-to-noise ratio. The 
standard that exhibited a signal five times greater than the background noise was then 
selected as the LOD for fentanyl.  
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2.13 Limit of Quantitation (LOQ).  
LODs represent the lowest quantity that can be distinguished from a blank, 
whereas LOQs define our range of quantitation for the assay. The lowest limit of 
quantitation (LLOQ) was chosen to be the lowest nonzero calibrator that demonstrated 
acceptable bias and precision (<20, >80%), along with reproducible chromatography. The 
upper limit of quantitation (ULOQ) was selected as the highest calibrator within the 
calibration range (i.e., 10.0 ng mL−1 for all IMF analogues except for fentanyl and 
norfentanyl at 50.0 ng mL−1). 
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Table 2. Retention Times, Limit of Detection (LOD), Lower Limit of Quantitation (LLOQ), and Linear Ranges for IMF Analogues (N = 22) 
along with Corresponding Internal Standards
ª
 
Analyte Internal 
Standard 
Retention 
Time 
(min) 
LOD 
(ng mL-1) 
LLOQ 
(ng mL-1) 
Linear Range 
(ng mL-1) 
Norfentanyl Norfentanyl-d5 7.62 0.038 0.100 0.100 – 50.0 
Furanyl norfentanyl Norfentanyl-d5 7.90 0.058 0.250 0.250 – 10.0 
Remifentanil acid Norfentanyl-d5 7.99 0.100 0.500 0.500 – 10.0 
Butyryl norfentanyl Norfentanyl-d5 8.04 0.044 0.100 0.100 – 10.0 
Remifentanil Fentanyl-d5 8.33 0.053 0.100 0.100 – 10.0 
Acetyl fentanyl AcetylFentanyl-
13C6 
8.68 0.017 0.100 0.100 – 10.0 
Alfentanil Fentanyl-d5 8.77 0.048 0.100 0.100 – 10.0 
AH-7921 Fentanyl-d5 8.96 0.042 0.100 0.100 – 10.0 
U-47700 Fentanyl-d5 8.85 0.019 0.100 0.100 – 10.0 
Acetyl fentanyl 4-
methylphenethyl 
Fentanyl-d5 8.97 0.037 0.100 0.100 – 10.0 
Acrylfentanyl Fentanyl-d5 8.99 0.034 0.100 0.100 – 10.0 
Fentanyl Fentanyl-d5 9.01 0.050 0.100 0.100 – 50.0 
para-Methoxyfentanyl Fentanyl-d5 9.11 0.056 0.100 0.100 – 10.0 
4-ANPP Fentanyl-d5 9.13 0.025 0.100 0.100 – 10.0 
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Furanyl fentanyl Fentanyl-d5 9.17 0.029 0.100 0.100 – 10.0 
Despropionyl para-
Fluorofentanyl 
Fentanyl-d5 9.19 0.016 0.100 0.100 – 10.0 
Carfentanil Fentanyl-d5 9.26 0.050 0.100 0.100 – 10.0 
()-cis-3-Methyl fentanyl Fentanyl-d5 9.24 0.048 0.250 0.250 – 10.0 
Butyryl/Isobutyryl 
fentanyl 
Fentanyl-d5 9.27 0.026 0.100 0.100 – 10.0 
para-Fluorobutyryl/para-
Fluoroisobutyryl fentanyl 
Fentanyl-d5 9.33 0.042 0.100 0.100 – 10.0 
Sufentanil Fentanyl-d5 9.42 0.100 0.250 0.250 – 10.0 
Valeryl fentanyl 
ªN = 3 
Fentanyl-d5 9.54 0.047 0.100 0.100 – 10.0 
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2.14 Selectivity/Specificity.  
All IMF analogues were evaluated for endogenous and exogenous interferences. 
Endogenous interferences were evaluated (N = 5) daily with whole blood previously 
screening negative for targeted IMF analogues. Negative blanks were extracted daily to 
assess false positive results due to potential matrix interferences. All negative blanks 
revealed no interferences were present that could result in a false positive identification.  
Exogenous interferences were measured with solutions containing N = 70 
commonly detected analytes in toxicology laboratories (Table S1). Verification of 
selectivity included extracting each commonly detected analyte at the concentration level 
specified in Table S1 and spiking with 0.35 ng mL−1 targeted IMF analytes in whole 
blood. Specificity was addressed by analyzing all N = 70 nontargeted analytes in whole 
blood without the addition of IMF analogues. False positives were not detected with 
nontargeted analytes, but large concentrations of benzodiazepine (2500 ng mL−1) were 
found to interfere with AH-7921 and U-47700. However, these concentrations are much 
larger than usually seen in normal assays.  
2.15 Recovery.  
SPE extraction recoveries were determined by analyzing post extraction spikes 
against regular extractions. Recoveries were determined using LOCTRL, MEDCTRL, 
and HICTRL (N = 3). The average recoveries for LOCTRL, MEDCTRL, and HICTRL 
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were 84 ± 19, 78 ± 12, and 94 ± 4.1%, respectively, for all N = 21 nonisomeric IMF 
analogues (excluding butyryl/isobutyryl fentanyl and para-fluorobutyryl/ para-
fluoroisobutyryl fentanyl). Recovery ranges for LOCTRL, MEDCTRL, and HICTRL 
were 38−140, 33−96, and 91−97%, respectively. All recovery values can be found in 
Table S2.  
2.16 Ionization Suppression/Enhancement (ISE).  
Ion suppression and enhancement (ISE) was evaluated using post extraction 
additions that were compared with neat standards. The signal response exhibited minor 
changes in most IMF analogues. Remifentanil acid exhibited the lowest ISE (<45%). The 
detection of each analyte was not affected by ISE. All ISE values can be found in Table 
S3.  
2.17 Process Efficiency.  
The total process efficiency was determined for each IMF analogue by 
comparison of neat standards against regular extractions. The process efficiency for 
LOCTRL, MEDCTRL, and HICTRL were 80 ± 13, 76 ± 12, and 89 ± 1.3%, respectively, 
for all IMF analogues. Process efficiency ranges for LOCTRL, MEDCTRL, and HICTRL 
were 45−104, 41−91, and 88−90%, respectively. All process efficiency values can be 
found in Table S4.  
Statistical quantitation of each IMF analogue followed immediately after 
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qualitative evaluation. Structural isomers that coeluted with each other were only 
qualitatively determined. Quantitative determination of drugs is normally important for 
toxicological analyses; however, taking into account the paucity of data available on 
IMFs, the qualitative identification of an IMF is more important than its quantity. All 
other IMF analogues were evaluated for bias and precision to meet acceptable criteria.28  
2.18 Bias and Precision.  
Intra- and interday bias and precision were assessed with the help of quality 
control samples containing all IMF analogues (0.35, 2.5, and 25.0 ng mL−1 of IMF 
analogues). Intraday bias and precision were expressed as the largest calculated bias and 
precision for each of the 5 days of the validation period. All other bias and precision 
values fell below the maximum intraday value (Table 3). Any IMF analogue not meeting 
acceptable criteria (bias < 20% and precision > 80%) was defined as qualitative only. 
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Table 3. Intra- and Interday Bias and Precision for All IMF Analogues Excluding the Isomerica 
    Bias (%)---  Precision (% 
CV) 
Analyte Expected 
Concentration 
(ng mL-1) 
Mean 
(ng mL-1) 
Inter-
day  
n = 3 
Intra-day 
n = 3 
Inter-
day  
n = 3 
Intra-
day 
n = 3 
norfentanyl 0.350 
2.5 
25 
0.3652 ± 0.011 
2.722 ± 0.17 
27.13 ± 0.67 
8.6 
18.0 
10.0 
4.3 
8.9 
8.5 
97.7 
94.3 
98.3 
97.0 
93.5 
97.4 
furanyl norfentanyl 0.350 
2.5 
0.3179 ± 0.023 
2.351 ± 0.21 
17.0 
9.3 
9.2 
6.0 
86.0 
78.0 
92.5 
91.0 
remifentanil acid 0.350 
2.5 
0.3211 ± 0.052 
2.327 ± 0.32 
14.0 
17.0 
8.3 
6.9 
72.0 
83.0 
83.0 
86.0 
butyryl norfentanyl 0.350 
2.5 
0.3630 ± 0.027 
2.602 ± 0.20 
17.0 
18.0 
3.7 
4.1 
94.3 
94.1 
92.4 
92.0 
remifentanil 0.350 
2.5 
0.3353 ± 0.017 
2.339 ± 0.17 
8.7 
12.0 
4.2 
6.4 
94.1 
94.0 
94.7 
92.6 
acetyl fentanyl 0.350 
2.5 
0.3478 ± 0.015 
2.579 ± 0.21 
6.4 
17.0 
0.63 
3.2 
97.9 
93.7 
95.7 
91.6 
alfentanil 0.350 
2.5 
0.3210 ± 0.019 
2.373 ± 0.15 
12.0 
9.4 
8.3 
5.1 
90.9 
92.9 
93.8 
93.6 
AH-7921 0.350 
2.5 
0.2722 ± 0.11 
1.761 ± 0.65 
65.0 
55.0 
22.0 
30.0 
-32.0 
4.0 
59.0 
62.0 
U-47700 0.350 
2.5 
0.3466 ± 0.038 
2.292 ± 0.15 
13.0 
14.0 
0.97 
8.3 
87.0 
92.0 
89.0 
93.3 
acetyl fentanyl 4-methylphenethyl 0.350 
2.5 
0.3628 ± 0.015 
2.556 ± 0.15 
8.8 
9.0 
3.7 
2.2 
94.7 
92.7 
95.8 
93.9 
acrylfentanyl 0.350 
2.5 
0.3507 ± 0.014 
2.502 ± 0.095 
5.0 
4.4 
0.20 
0.096 
94.9 
96.1 
96.0 
96.1 
fentanyl 0.350 
2.5 
0.3326 ± 0.015 
2.458 ± 0.15 
13.0 
8.0 
5.0 
1.7 
98.2 
95.1 
95.3 
93.5 
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25 24.77 ± 1.5 6.2 0.92 88.0 93.6 
para-methoxyfentanyl 0.350 
2.5 
0.3598 ± 0.018 
2.533 ± 0.12 
9.1 
7.5 
2.8 
1.3 
92.5 
93.8 
94.7 
95.2 
4-ANPP 0.350 
2.5 
0.3306 ± 0.043 
2.373 ± 0.32 
20.0 
20.0 
5.5 
5.1 
76.0 
84.0 
87.0 
86.0 
furanyl fentanyl 0.350 
2.5 
0.3426 ± 0.015 
2.487 ± 0.12 
4.4 
5.4 
2.1 
0.53 
94.6 
95.3 
95.5 
95.0 
despropionyl para-fluorofentanyl 0.350 
2.5 
0.2819 ± 0.044 
2.006 ± 0.33 
23.0 
37.0 
19.0 
20.0 
71.0 
81.0 
84.0 
83.0 
carfentanil 0.350 
2.5 
0.3281 ± 0.011 
2.366 ± 0.11 
9.7 
9.9 
6.3 
5.3 
96.6 
91.9 
96.5 
95.1 
()-cis-3-Methyl fentanyl 0.350 
2.5 
0.3419 ± 0.030 
2.418 ± 0.24 
18.0 
20.0 
2.3 
3.3 
94.1 
94.0 
91.0 
90.0 
butyryl/isobutyryl fentanyl 0.350 
2.5 
0.4488 ± 0.20 
3.348 ± 1.4 
86.0 
95.0 
28.0 
34.0 
26.0 
31.0 
54.0 
55.0 
para-fluorobutyryl/para-fluoroisobutyryl 
fentanyl 
0.350 
2.5 
0.3665 ± 0.042 
2.709 ± 0.26 
19.0 
19.0 
4.7 
8.4 
92.1 
96.3 
88.0 
90.1 
vufentanil 0.350 
2.5 
0.2903 ± 0.035 
2.074 ± 0.16 
30.0 
26.0 
17.0 
17.0 
87.0 
93.3 
88.0 
91.9 
valeryl fentanyl 
 
0.350 
2.5 
0.3492 ± 0.015 
2.480 ± 0.11 
6.0 
5.1 
0.23 
0.80 
95.3 
95.9 
95.7 
95.3 
aIsomeric IMFs include butyryl, isobutyryl fentanyl, para-fluorobutyryl fentanyl, and FIBF. Underlined IMF analogues refer to successful 
quantitation that met acceptable criteria. 
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3. Results and Discussion 
The LC-MS/MS method developed in this study allows for the multiplex 
detection of N = 24 IMF analytes with good sensitivity and a short sample run time (13.5 
min). Quantitated IMF analogues (N = 13) passed all evaluations. These were 
norfentanyl, butyryl norfentanyl, remifentanil, acetyl fentanyl, alfentanil, U-47700, acetyl 
fentanyl 4-methylphenethyl, acrylfentanyl, fentanyl, para-methoxyfentanyl, furanyl 
fentanyl, carfentanil, and valeryl fentanyl. All analytes had an LOD ≤ 0.100 ng mL−1 and 
a maximum LLOQ of 0.500 ng mL−1 (the lowest LLOQ value being 0.100 ng mL−1).  
3.1 Casework  
Since its development and validation in January 2017, the LC-MS/MS method 
was successfully utilized in the IMF analysis of N = 725 blood samples at the 
Montgomery County Coroner’s Office (MCCO) in Dayton, Ohio. The postmortem 
samples were collected from accidental drug overdose death cases that occurred between 
February 2015 and November 2016. The MCCO laboratory provides postmortem 
forensic toxicology services to approximately 40 of Ohio’s 88 counties. The following N 
= 10 IMF analogues were found to be present in the analyzed samples: (±)-cis-3-methyl 
fentanyl, 4-ANPP, acetyl fentanyl, carfentanil, despropionyl para-fluorofentanyl, 
fentanyl, furanyl fentanyl, furanyl norfentanyl, norfentanyl, and U-47700.  
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Table 4. Total number of times each IMF analog was detected in the N = 725 cases of unintentional drug overdose 
death. 
IMF Analog Number of times detected 
(±)-cis-3-methyl fentanyl 1 
4ANPP 82 
Acetyl fentanyl 40 
Carfentanil 22 
Despropionyl fluorofentanyl 1 
Fentanyl 662 
Furanyl fentanyl 39 
Furanyl norfentanyl 2 
Norfentanyl 582 
U-47700 3 
 
Table 4 summarizes the total number of times each IMF analogue was detected 
across the N = 725 whole blood samples. Fentanyl (N = 662, 91%) and its metabolite, 
norfentanyl (N = 582, 80%), were the most commonly encountered in the examined 
cases. Furthermore, N = 82 cases (11%) tested positive for 4-ANPP, which is an impurity 
related to the synthesis of fentanyl and also a metabolite of fentanyl. There were also 40 
acetyl fentanyl (6%), 39 furanyl fentanyl (5%), and 22 carfentanil (3%) positive cases.  
The analysis of more recent accidental overdose cases at MCCO laboratory that 
occurred in between January and February 2017, identified N = 13 IMF analogues 
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(fentanyl, acrylfentanyl, furanyl fentanyl, carfentanil, norfentanyl, despropionyl fentanyl 
(4-ANPP), despropionyl para-fluorofentanyl, furanyl norfentanyl, acetyl fentanyl, 
butyryl/isobutyryl fentanyl, butyryl norfentanyl, fluorobutyryl/fluoroisobutyryl fentanyl, 
and U-47700).29  
 
Figure 5. Quantitative ion chromatogram of an accidental overdose case from late 2016. Abbreviations are as follows: 
(1) norfentanyl-d
5
, (2) norfentanyl, (8) acetyl fentanyl 
13
C
6
, (10) U-47700, (13) fentanyl, (15) fentanyl-d
5
, (16) 4-ANPP, 
(18) furanyl fentanyl, (19) despropionyl para-fluorofentanyl, (21) butyryl/isobutyryl fentanyl, and (23) para-
fluorobutyryl/para-fluoroisobutyryl fentanyl. Inset shows the low-response count region of IMF analogues. 
Figure 3 illustrates the recent, multiplex detection of N = 8 IMF analogues from a single 
whole blood sample at MCCO along with their corresponding concentrations: norfentanyl 
 (0.47 ng mL-1 ), U-47700 (0.50 ng mL-1 ), fentanyl (1.2 ng mL−1), and furanyl fentanyl 
(1.5 ng mL−1). Because of cases like this, it is critical to incorporate such flexible 
methods into the routine toxicological analysis at forensic laboratories worldwide. A 
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second manuscript is in production, in which N = 725 cases will be discussed in detail.  
3.2 Knowledge Gaps 
Several previous studies
8−10,30−35 have already demonstrated the capabilities of the 
LC-MS/MS-based analytical method in detecting IMF analogues, in the 0.050−0.500 ng 
mL−1 concentration range.
10 However, the LOQ was determined to be the lowest 
calibrator at 0.100 ng mL−1, which is equivalent to the LOQ value of this study. To the 
best of our knowledge, these LC-MS/MS studies on human blood detected at most N = 
17 IMF analogues and homologues with a 35 min scan time but without quantitation.
30 
Furthermore, those LC-MS/MS methods that offered quantitation did not tackle more 
than N = 9 IMF analogues.
35 As the frequency of opioid abuse cases is drastically 
increasing both in the forensic and clinical world, both the qualitative identification and 
quantitation of such analytes is becoming equally important.
36 The LC-MS/MS method of 
this study will address this deficit by facilitating both the identification (N = 22) and 
quantification (N = 13 for illustrative purposes) of IMF analogues and metabolites (total 
of N = 24 of the most commonly encountered IMFs in human blood) down to 0.100 ng 
mL−1, i.e., the lowest LOQ reported to date according to our knowledge. Additionally, 
this LC-MS/ MS method can be easily adapted to accommodate newly emerging IMFs in 
various drug analysis settings and with the shortest screening time (13.5 min) under the 
studied conditions.  
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Other analytical methods, such as gas chromatography−mass spectrometry 
(GC−MS)
37 and thermal desorption direct analysis in real time mass spectrometry,
38 have 
also been explored. Although successful in the qualitative detection of N = 17 and 
quantitation of N = 4 IMF analogues and metabolites, these methods had greater LODs 
(0.08−0.351 ng mL−1) and LLOQs (0.500 ng mL−1) than the ones described in this LC-
MS/MS method, namely, 0.017−0.050 and 0.100 ng mL−1, respectively, for all N = 13 
quantitated IMF analogues.  
4. Conclusion 
An LC-MS/MS-based method was developed for the multiplex detection of N = 
24 IMF analogues and metabolites in postmortem blood at sub ng mL
−1 concentrations. It 
was successfully implemented at the Montgomery County Coroner’s Office/Miami 
Valley Regional Crime Laboratory in Dayton, Ohio, where it aided in the analysis of N = 
725 postmortem blood samples collected from accidental drug overdose death cases. This 
forensic work demonstrated the cost- and time-efficiency of the newly developed IMF 
detection method. In addition to employing commercially available, inexpensive supplies 
and common forensic instrumentation, the method requires 13.5 min scan time for a 
single sample and 5− 10 min for quantitative and qualitative analysis. The LC-MS/MS-
based protocol can be easily adapted by forensic laboratories worldwide; it is currently 
undergoing modifications to incorporate the addition of four new IMF analogues (β-
hydroxythiofentanyl, para-fluorofentanyl, tetrahydrofuran fentanyl, and cyclopropyl 
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fentanyl) at the Montgomery County Coroner’s Office.  
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Supporting Information 
 
 
Figure S1. MPA and MPB gradient concentration change over a 13.5 minute per sample 
run period. 
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Table S1. Drugs commonly detected in forensic toxicology casework (N = 70) and tested 
in this study for exogenous interferences. 
Injection Mix Drugs included in the interference study test mix 
Concentration 
(ng mL-1) 
Benzodiazepines 
7-Aminoclonazepam, 7-Aminoflunitrazepam, 
Alprazolam, Chlordiazepoxide, Clonazepam, Diazepam, 
Flunitrazepam, Flurazepam, Lorazepam, Midazolam, 
Nordiazepam, Oxazepam, Phenazepam, Temazepam, 
Triazolam 
2,500 
Opiates 
Hydrocodone, Hydromorphone*, Oxycodone, Morphine, 
Oxymorphone*, 6-Acetylmorphine*, Codeine 
2,500* 
10,000 
Stimulants 
Cocaine, Cocaethylene, Ecgonine methyl ester, 
Benzoylecgonine, Amphetamine, Phenylpropanolamine, 
Phentermine, Methamphetamine, Pseudoephedrine, 
Methylenedioxyamphetamine, Benzyl piperazine, 
Methylenedioxymethamphetamine, 
Methylenedioxyethylamphetamine, Methylphenidate 
1,250  
THC 
11-nor-9-carboxy Tetrahydrocannabinol*, 
Tetrahydrocannabinol 
1,250* 
500 
Bases 
Chlorpheniramine, Citalopram, Dextromethorphan, 
Doxylamine, Lidocaine, Methadone, Mirtazapine, 
Tramadol, Trazodone, Verapamil, Zolpidem 
1,250 
AD 
Venlafaxine, Desvenlafaxine, Quetiapine, Paroxetine, 
Desipramine, Norfluoxetine, Imipramine, Fluoxetine, 
Nortriptyline, Cyclobenzaprine, Amitriptyline, Sertraline, 
Duloxetine 
1,250 
AE 
Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, 
Topiramate, Zonisamide 
5,000 
GHB Gamma hydroxybutyric acid 50,000 
Rx Naloxone 10,000 
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Table S2. Recovery percentages for N =22 illicitly manufactured fentanyl (IMF) analogs 
and metabolites at low (0.35 ng mL-1), medium (2.5 ng mL-1), and high control 
concentrations (25.0 ng mL-1). Set #1 and #2 refer to post extraction spiked and regular 
extraction samples, respectively. 
Norfentanyl 
 Set #1    Set #2   
Trial no. Low Med High  Low Med High 
1 17631.48 140730.77 1000604.93  13814.81 108589.51 894437.11 
2 18047.00 137202.97 829527.44  14056.68 89730.02 960464.26 
3 18557.65 130331.00 1175213.13  16278.87 101081.64 872363.61 
Average 18078.71 136088.25 1001781.83  14716.78 99800.39 909088.33 
Recovery (%) 81.40 73.34 90.75     
Furanyl norfentanyl 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 4590.15 31704.02 230975.70  2561.18 25373.77 203161.69 
2 5487.52 28719.55 212752.81  2868.62 15808.62 254305.58 
3 5446.13 27056.84 304847.16  3643.37 17184.88 197428.08 
Average 5174.60 29160.14 249525.22  3024.39 19455.76 218298.45 
Recovery (%) 58.45 66.72 87.49*     
Remifentanil acid 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 2089.06 16561.54 167171.23  888.60 5835.51 50776.07 
2 2334.54 16266.17 157158.90  800.58 4657.90 52331.12 
3 2339.62 15863.99 155740.28  885.15 5417.15 49659.41 
Average 2254.40 16230.56 160023.47  858.11 5303.52 50922.20 
Recovery (%) 38.06 32.68 31.82*     
Butyryl norfentanyl 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 19330.65 177026.12 1153778.73  18740.57 135942.06 1035652.82 
2 21813.09 175292.19 934465.45  17835.67 118133.80 1076581.04 
3 20551.76 168768.33 1307357.39  21253.04 129095.32 992372.29 
Average 20565.17 173695.55 1131867.19  19276.43 127723.73 1034868.72 
36 
 
Recovery (%) 93.73 73.53 91.43*     
Remifentanil 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 3398.58 25879.27 247196.84  2769.84 19518.17 206515.06 
2 3631.82 26098.03 251472.03  2732.97 16166.15 214967.39 
3 3855.28 23094.96 262547.87  2863.09 20413.23 191769.16 
Average 3628.56 25024.09 253738.91  2788.64 18699.18 204417.20 
Recovery (%) 76.85 74.72 80.56*     
Acetyl fentanyl 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 39163.01 307276.32 2737509.47  32202.32 242612.47 2319607.20 
2 39599.84 295551.80 2686140.35  31485.04 208628.84 2443187.71 
3 41336.33 279207.70 2690796.28  35728.32 246516.70 2248135.27 
Average 40033.06 294011.94 2704815.37  33138.56 232586.00 2336976.72 
Recovery (%) 82.78 79.11 86.40*     
Alfentanil 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 16613.52 111052.10 1069888.51  9410.82 83578.37 829356.47 
2 16148.05 106762.53 1091804.94  10494.02 68625.62 847084.67 
3 16345.64 96063.01 1030880.31  11468.14 85460.45 800546.70 
Average 16369.07 104625.88 1064191.25  10457.66 79221.48 825662.61 
Recovery (%) 63.89 75.72 77.59     
AH-7921* 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 5425.16 41519.09 171578.91  4987.49 30028.21 268991.42 
2 5448.88 38275.23 187181.59  4626.44 29397.38 299962.16 
3 5587.03 35003.78 317460.45  4828.00 33563.29 248723.39 
Average 5487.02 38266.03 225406.98  4813.98 30996.29 272558.99 
Recovery (%) 87.73 81.00 120.92*     
U-47700 
 Set #1    Set 2   
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Trial no. Low Med High*  Low Med High* 
1 8789.37 69172.60 663875.37  7419.27 55748.60 525822.70 
2 7814.93 65002.70 675335.12  7911.76 51056.55 554450.77 
3 9579.90 60507.01 611724.71  8857.27 53830.68 501931.10 
Average 8728.06 64894.10 650311.73  8062.76 53545.28 527401.53 
Recovery (%) 92.38 82.51 81.10*     
Acetyl fentanyl 4-methylphenethyl 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 43670.09 362857.36 3004272.27  39273.94 294742.30 2564883.21 
2 49639.28 358218.25 2896594.04  40145.21 270667.02 2671448.69 
3 52373.23 325855.55 2865642.66  46585.53 276548.83 2533831.52 
Average 48560.87 348977.05 2922169.66  42001.56 280652.71 2590054.47 
Recovery (%) 86.49 80.42 88.63*     
Acrylfentanyl 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 46580.17 341583.14 2646397.46  37202.88 281712.87 2428913.55 
2 46952.36 337096.36 2475688.79  37972.97 242770.34 2537661.55 
3 48849.41 310714.29 2705321.61  43752.84 287579.53 2351749.58 
Average 47460.65 329797.93 2609135.95  39642.89 270687.58 2439441.56 
Recovery (%) 83.53 82.08 93.50*     
Fentanyl 
 Set #1    Set #2   
Trial no. Low Med High  Low Med High 
1 36202.96 270883.19 2119693.09  29709.08 227320.04 2041829.06 
2 35742.90 270642.79 2000594.92  29167.22 198024.25 2134377.46 
3 36708.57 245358.38 2271119.18  35764.60 218804.82 1996871.66 
Average 36218.14 262294.79 2130469.06  31546.97 214716.37 2057692.73 
Recovery (%) 87.10 81.86 96.58     
para-Methoxyfentanyl 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 27904.20 216676.89 1614255.82  22788.33 171129.57 1444155.49 
2 28721.90 201953.30 1627239.48  22972.15 154837.11 1453530.64 
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3 27416.76 187643.49 1650187.28  28583.31 181306.70 1446219.28 
Average 28014.29 202091.22 1630560.86  24781.26 169091.13 1447968.47 
Recovery (%) 88.46 83.67 88.80*     
4-ANPP 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 166174.74 1261945.01 8907584.39  190178.80 
1229445.0
2 
8369358.55 
2 164486.85 1336291.01 7977401.72  180041.98 
1076604.7
1 
8607365.57 
3 153677.98 1223611.13 9025869.40  202286.59 
1208246.0
4 
7867551.53 
Average 161446.52 1273949.05 8636951.83  190835.79 
1171431.9
2 
8281425.22 
Recovery (%) 118.20 91.95 95.88*     
Furanyl fentanyl 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 52810.26 387507.42 2941574.99  43119.60 311988.90 2601610.85 
2 55872.20 383238.32 2976957.89  42896.47 273618.10 2713430.81 
3 54758.43 355667.52 3015865.39  49315.64 319827.23 2468265.83 
Average 54480.30 375471.09 2978132.76  45110.57 301811.41 2594435.83 
Recovery (%) 82.80 80.38 87.12*     
Despropionyl para-fluorofentanyl 
 Set #1    Set #2   
Trial no. Low: Med High*  Low Med High* 
1 32789.88 314597.61 2611783.53  44611.95 298602.77 2379969.31 
2 32015.33 308942.79 2020791.13  42323.78 262062.45 2461242.98 
3 32208.91 279852.22 2524003.09  48160.70 302515.48 2219544.67 
Average 32338.04 301130.88 2385525.92  45032.14 287726.90 2353585.65 
Recovery (%) 139.25 95.55 98.66*     
(±)-cis-3-Methyl fentanyl 
 Set 1    Set 2   
Trial no. Low Med High*  Low Med High* 
1 29995.09 191506.88 1699602.14  20491.67 156986.46 1478382.82 
2 27567.04 188660.85 1677071.23  21452.07 141056.37 1509950.96 
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3 30375.57 168344.98 1696079.64  23994.77 155435.24 1401345.31 
Average 29312.57 182837.57 1690917.67  21979.50 151159.36 1463226.36 
Recovery (%) 74.98 82.67 86.53*     
Butyryl/Isobutyrl fentanyl 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 43402.19 351851.45 2988080.64  39780.73 286850.10 2561000.97 
2 45696.44 347785.05 2928941.15  40474.67 250218.59 2732200.06 
3 45562.36 310423.46 2915792.27  41938.47 284702.64 2492138.07 
Average 44887.00 336686.65 2944271.35  40731.29 273923.77 2595113.03 
Recovery (%) 90.74 81.36 88.14*     
Carfentanil 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 26402.18 190896.65 1252684.53  20082.97 141783.79 1156826.21 
2 26772.94 193793.45 1293548.17  19522.51 125922.13 1232173.90 
3 27415.09 164202.38 1352347.09  21596.45 150266.11 1127003.16 
Average 26863.40 182964.16 1299526.60  20400.64 139324.01 1172001.09 
Recovery (%) 75.94 76.15 90.19*     
para-Fluorobutyryl fentanyl/FIBF 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 56583.98 381385.01 3052026.12  40598.62 312539.77 2654829.38 
2 58804.88 378836.24 2952835.55  39133.46 276976.56 2748411.38 
3 55929.45 348080.56 3027438.83  46283.60 320551.42 2534921.27 
Average 57106.10 369433.94 3010766.83  42005.23 303355.92 2646054.01 
Recovery (%) 73.56 82.11 87.89*     
Sufentanil 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 23138.46 154831.15 1361946.43  16366.94 120199.93 1242166.50 
2 23670.37 148236.77 1328720.78  15683.01 110473.97 1269157.94 
3 24917.06 133487.14 1383698.29  19433.81 121634.57 1138826.22 
Average 23908.63 145518.35 1358121.83  17161.25 117436.15 1216716.88 
Recovery (%) 71.78 80.70 89.59*     
40 
 
Valeryl fentanyl 
 Set 1    Set 2   
Trial no. Low Med High*  Low Med High* 
1 56843.33 462938.62 3830025.05  51047.18 370795.17 3328155.43 
2 61663.39 453705.57 3921682.44  50457.26 327512.59 3497367.43 
3 59012.31 424183.71 3828719.32  58040.14 369396.01 3238100.13 
Average 59173.01 446942.63 3860142.27  53181.53 355901.26 3354541.00 
Recovery (%) 89.87 79.63 86.90*     
 
*Recovery percentages for all IMF analogs except for fentanyl and norfentanyl were estimated 
only theoretically at the high control concentration, where the control concentration exceeded the 
calibration range. 
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Table S3. Ionization suppression and enhancement percentages for N = 22 illicitly 
manufactured fentanyl (IMFs) analogs at low (0.35 ng mL-1), medium (2.5 ng mL-1), and 
high control concentrations (25.0 ng mL-1). Set #1 and #2 refer to regular and neat quality 
standards, respectively. 
Norfentanyl 
 Set #1    Set #2   
Trial no. Low  Med High  Low Med High 
1 16183.09 112346.21 1040696.84  17631.48 140730.77 1000604.93 
2 16400.53 110543.30 1001399.58  18047.00 137202.97 829527.44 
3 15576.46 120348.17 1069657.21  18557.65 130331.00 1175213.13 
Average 16053.36 114412.56 1037251.21  18078.71 136088.25 1001781.83 
Matrix Effect 
(%) 
112.62 118.95 96.58     
Furanyl norfentanyl 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 4565.76 26311.47 282170.68  4590.15 31704.02 230975.70 
2 4934.86 27258.58 196048.07  5487.52 28719.55 212752.81 
3 4379.86 27359.57 295672.89  5446.13 27056.84 304847.16 
Average 4626.83 26976.54 257963.88  5174.60 29160.14 249525.22 
Matrix Effect 
(%) 
111.84 108.09 96.73*     
Remifentanil acid 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 1912.22 13115.17 148736.10  2089.06 16561.54 167171.23 
2 2044.45 12727.17 158545.18  2334.54 16266.17 157158.90 
3 1799.16 13111.16 146491.63  2339.62 15863.99 155740.28 
Average 1918.61 12984.50 151257.64  2254.40 16230.56 160023.47 
Matrix Effect 
(%) 
117.50 125.00 105.80*     
        
Butyryl norfentanyl 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 17944.00 133950.12 1168174.85  19330.65 177026.12 1153778.73 
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2 19068.89 136111.96 1178733.62  21813.09 175292.19 934465.45 
3 18347.13 146972.56 1186049.58  20551.76 168768.33 1307357.39 
Average 18453.34 139011.55 1177652.68  20565.17 173695.55 1131867.19 
Matrix Effect 
(%) 
111.44 124.95 96.11*     
Remifentanil 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 3698.61 24148.82 245580.98  3398.58 25879.27 247196.84 
2 4110.52 31187.58 258044.21  3631.82 26098.03 251472.03 
3 3395.64 30361.85 270170.79  3855.28 23094.96 262547.87 
Average 3734.92 28566.08 257931.99  3628.56 25024.09 253738.91 
Matrix Effect 
(%) 
97.15 87.60 98.37*     
        
Acetyl Fentanyl 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 32900.81 272480.22 2696875.16  39163.01 307276.32 2737509.47 
2 38733.20 274894.98 2701173.97  39599.84 295551.80 2686140.35 
3 38518.67 280970.95 2735233.43  41336.33 279207.70 2690796.28 
Average 36717.56 276115.38 2711094.19  40033.06 294011.94 2704815.37 
Matrix Effect 
(%) 
109.03 106.48 99.77*     
Alfentanil 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 16619.67 112384.98 1045263.57  16613.52 111052.10 1069888.51 
2 18109.61 118183.23 1046701.52  16148.05 106762.53 1091804.94 
3 17756.09 119055.84 1092001.13  16345.64 96063.01 1030880.31 
Average  17495.12 116541.35 1061322.07  16369.07 104625.88 1064191.25 
Matrix Effect 
(%) 
93.56 89.78 100.27*     
AH7921 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
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1 6566.28 48615.06 476009.13  5425.16 41519.09 171578.91 
2 7633.34 48108.20 473702.01  5448.88 38275.23 187181.59 
3 6878.39 47187.37 467335.92  5587.03 35003.78 317460.45 
Average 7026.00 47970.21 472349.02  5487.02 38266.03 225406.98 
Matrix Effect 
(%) 
78.10 79.77 47.72*     
U-47700 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 9035.57 60676.63 598626.36  8789.37 69172.60 663875.37 
2 8841.10 60748.85 589120.64  7814.93 65002.70 675335.12 
3 9052.78 61807.71 555878.02  9579.90 60507.01 611724.71 
Average 8976.48 61077.73 581208.34  8728.06 64894.10 650311.73 
Matrix Effect 
(%) 
97.23 106.25 111.89*     
Acetyl fentanyl 4-methylphenethyl 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 48878.21 329056.56 2764066.69  43670.09 362857.36 3004272.27 
2 49041.99 317459.70 2771548.48  49639.28 358218.25 2896594.04 
3 46270.71 329783.06 2784287.37  52373.23 325855.55 2865642.66 
Average 48063.64 325433.11 2773300.84  48560.87 348977.05 2922169.66 
Matrix Effect 
(%) 
101.03 107.23 105.37*     
Acrylfentanyl 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 43882.58 308992.39 2536934.84  46580.17 341583.14 2646397.46 
2 46517.72 293356.95 2596363.31  46952.36 337096.36 2475688.79 
3 44189.23 305741.89 2595711.68  48849.41 310714.29 2705321.61 
Average 44863.18 302697.08 2576336.61  47460.65 329797.93 2609135.95 
Matrix Effect 
(%) 
105.79 108.95 101.27*     
Fentanyl 
 Set #1    Set #2   
Trial no. Low Med High  Low Med High 
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1 35121.93 243862.09 2277257.74  36202.96 270883.19 2119693.09 
2 36338.33 272959.43 2236877.77  35742.90 270642.79 2000594.92 
3 37012.04 266771.73 2381041.33  36708.57 245358.38 2271119.18 
Average 36157.43 261197.75 2298392.28  36218.14 262294.79 2130469.06 
Matrix Effect 
(%) 
100.17 100.42 92.69     
para-Methoxyfentanyl 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 27910.62 182350.93 1495982.69  27904.20 216676.89 1614255.82 
2 28307.99 187967.00 1560701.40  28721.90 201953.30 1627239.48 
3 27175.06 188179.96 1535007.01  27416.76 187643.49 1650187.28 
Average 27797.89 186165.96 1530563.70  28014.29 202091.22 1630560.86 
Matrix Effect 
(%) 
100.78 108.55 106.53*     
4ANPP 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 250705.82 1588320.59 10328356.33  166174.74 1261945.01 8907584.39 
2 258303.65 1581159.69 10153768.64  164486.85 1336291.01 7977401.72 
3 243397.40 1581703.72 10159658.74  153677.98 1223611.13 9025869.40 
Average 250802.29 1583728.00 10213927.90  161446.52 1273949.05 8636951.83 
Matrix Effect 
(%) 
64.37 80.44 84.56*     
Furanyl Fentanyl 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 49598.48 349942.60 2901533.55  52810.26 387507.42 2941574.99 
2 53154.12 346954.45 2836640.95  55872.20 383238.32 2976957.89 
3 51906.40 357217.84 2887911.90  54758.43 355667.52 3015865.39 
Average 51553.00 351371.63 2875362.13  54480.30 375471.09 2978132.76 
Matrix Effect 
(%) 
105.68 106.86 103.57*     
Despropionyl para-fluorofentanyl 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
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1 55310.89 410215.90 3346009.48  32789.88 314597.61 2611783.53 
2 59539.77 417208.83 3306663.71  32015.33 308942.79 2020791.13 
3 54462.41 429930.16 3259141.25  32208.91 279852.22 2524003.09 
Average 56437.69 419118.30 3303938.15  32338.04 301130.88 2385525.92 
Matrix Effect 
(%) 
57.30 71.85 72.20*     
(±)-cis-3-Methyl fentanyl 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 24054.35 166202.47 1583431.31  29995.09 191506.88 1699602.14 
2 27032.87 169935.48 1605989.18  27567.04 188660.85 1677071.23 
3 28262.03 170303.84 1617468.23  30375.57 168344.98 1696079.64 
Average 26449.75 168813.93 1602296.24  29312.57 182837.57 1690917.67 
Matrix Effect 
(%) 
110.82 108.31 105.53*     
Butyryl/Isobutyrl Fent 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 45422.09 314101.40 2930769.08  43402.19 351851.45 2988080.64 
2 43811.81 330407.44 2863257.61  45696.44 347785.05 2928941.15 
3 43617.99 318274.99 2892301.46  45562.36 310423.46 2915792.27 
Average 44283.97 320927.94 2895442.71  44887.00 336686.65 2944271.35 
Matrix Effect 
(%) 
101.36 104.91 101.69*     
Carfentanil 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 29581.26 190158.75 1361256.73  26402.18 190896.65 1252684.53 
2 28035.22 185363.84 1327128.00  26772.94 193793.45 1293548.17 
3 28947.85 186650.17 1340755.27  27415.09 164202.38 1352347.09 
Average 28854.78 187390.92 1343046.67  26863.40 182964.16 1299526.60 
Matrix Effect 
(%) 
93.10 97.64 96.76*     
para-Fluorobutyryl/FIBF 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
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1 54002.16 342912.34 2955695.73  56583.98 381385.01 3052026.12 
2 56611.46 339053.46 2918068.58  58804.88 378836.24 2952835.55 
3 58760.62 353647.81 2923275.93  55929.45 348080.56 3027438.83 
Average 56458.08 345204.54 2932346.74  57106.10 369433.94 3010766.83 
Matrix Effect 
(%) 
101.15 107.02 102.67*     
Sufentanil 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 21378.68 141092.61 1353710.93  23138.46 154831.15 1361946.43 
2 23467.13 133429.58 1365799.90  23670.37 148236.77 1328720.78 
3 21426.18 137804.06 1362923.38  24917.06 133487.14 1383698.29 
Average 22090.66 137442.08 1360811.40  23908.63 145518.35 1358121.83 
Matrix Effect 
(%) 
108.23 105.88 99.80*     
Valeryl Fentanyl 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 59939.19 373667.31 3834026.52  56843.33 462938.62 3830025.05 
2 62192.36 419395.23 3638907.11  61663.39 453705.57 3921682.44 
3 60773.11 434846.52 3925964.13  59012.31 424183.71 3828719.32 
Average 60968.22 409303.02 3799632.58  59173.01 446942.63 3860142.27 
Matrix Effect 
(%) 
97.06 109.20 101.59*     
*Ionization suppression and enhancement percentages for all IMF analogs except for fentanyl and 
norfentanyl were estimated only theoretically at the high control concentration, where the control 
concentration exceeded the calibration range. 
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 Table S4. Process efficiency percentages for N = 22 illicitly manufactured fentanyl 
(IMFs) analogs at low (0.35 ng mL-1), medium (2.5 ng mL-1), and high control 
concentrations (25.0 ng mL-1). Set #1 and #2 refer to neat quality standards and regular 
extractions, respectively. 
Norfentanyl 
 Set #1    Set #2   
Trial no. Low Med High  Low Med High 
1 16183.09 112346.21 1040696.84  13814.81 108589.51 894437.11 
2 16400.53 110543.30 1001399.58  14056.68 89730.02 960464.26 
3 15576.46 120348.17 1069657.21  16278.87 101081.64 872363.61 
Average 16053.36 114412.56 1037251.21  14716.78 99800.39 909088.33 
Process 
Efficiency 
(%) 
91.67 87.23 87.64     
Furanyl norfentanyl 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 4565.76 26311.47 282170.68  2561.18 25373.77 203161.69 
2 4934.86 27258.58 196048.07  2868.62 15808.62 254305.58 
3 4379.86 27359.57 295672.89  3643.37 17184.88 197428.08 
Average 4626.83 26976.54 257963.88  3024.39 19455.76 218298.45 
Process 
Efficiency 
(%) 
65.37 72.12 84.62*     
Remifentanil acid 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 1912.22 13115.17 148736.10  888.60 5835.51 50776.07 
2 2044.45 12727.17 158545.18  800.58 4657.90 52331.12 
3 1799.16 13111.16 146491.63  885.15 5417.15 49659.41 
Average 1918.61 12984.50 151257.64  858.11 5303.52 50922.20 
Process 
Efficiency 
(%) 
44.73 40.84 33.67*     
Butyryl norfentanyl 
 Set #1    Set #2   
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Trial no. Low Med High*  Low Med High* 
1 17944.00 133950.12 1168174.85  18740.57 135942.06 1035652.82 
2 19068.89 136111.96 1178733.62  17835.67 118133.80 1076581.04 
3 18347.13 146972.56 1186049.58  21253.04 129095.32 992372.29 
Average 18453.34 139011.55 1177652.68  19276.43 127723.73 1034868.72 
Process 
Efficiency 
(%) 
104.46 91.88 87.88*     
Remifentanil 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 3698.61 24148.82 245580.98  2769.84 19518.17 206515.06 
2 4110.52 31187.58 258044.21  2732.97 16166.15 214967.39 
3 3395.64 30361.85 270170.79  2863.09 20413.23 191769.16 
Average 3734.92 28566.08 257931.99  2788.64 18699.18 204417.20 
Process 
Efficiency 
(%) 
74.66 65.46 79.25*     
Acetyl Fentanyl 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 32900.81 272480.22 2696875.16  32202.32 242612.47 2319607.20 
2 38733.20 274894.98 2701173.97  31485.04 208628.84 2443187.71 
3 38518.67 280970.95 2735233.43  35728.32 246516.70 2248135.27 
Average 36717.56 276115.38 2711094.19  33138.56 232586.00 2336976.72 
Process 
Efficiency 
(%) 
90.25 84.24 86.20*     
Alfentanil 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 16619.67 112384.98 1045263.57  9410.82 83578.37 829356.47 
2 18109.61 118183.23 1046701.52  10494.02 68625.62 847084.67 
3 17756.09 119055.84 1092001.13  11468.14 85460.45 800546.70 
Average 17495.12 116541.35 1061322.07  10457.66 79221.48 825662.61 
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Process 
Efficiency 
(%) 
59.77 67.98 77.80*     
AH7921 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 6566.28 48615.06 476009.13  4987.49 30028.21 268991.42 
2 7633.34 48108.20 473702.01  4626.44 29397.38 299962.16 
3 6878.39 47187.37 467335.92  4828.00 33563.29 248723.39 
Average 7026.00 47970.21 472349.02  4813.98 30996.29 272558.99 
Process 
Efficiency 
(%) 
68.52 64.62 57.70*     
U-47700 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 9035.57 60676.63 598626.36  7419.27 55748.60 525822.70 
2 8841.10 60748.85 589120.64  7911.76 51056.55 554450.77 
3 9052.78 61807.71 555878.02  8857.27 53830.68 501931.10 
Average 8976.48 61077.73 581208.34  8062.76 53545.28 527401.53 
Process 
Efficiency 
(%) 
89.82 87.67 90.74*     
Acetyl fentanyl 4-methylphenethyl 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 48878.21 329056.56 2764066.69  39273.94 294742.30 2564883.21 
2 49041.99 317459.70 2771548.48  40145.21 270667.02 2671448.69 
3 46270.71 329783.06 2784287.37  46585.53 276548.83 2533831.52 
Average -----
--------------> 
48063.64 325433.11 2773300.84  42001.56 280652.71 2590054.47 
Process 
Efficiency 
(%) 
87.39 86.24 93.39*     
Acrylfentanyl 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
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1 43882.58 308992.39 2536934.84  37202.88 281712.87 2428913.55 
2 46517.72 293356.95 2596363.31  37972.97 242770.34 2537661.55 
3 44189.23 305741.89 2595711.68  43752.84 287579.53 2351749.58 
Average 44863.18 302697.08 2576336.61  39642.89 270687.58 2439441.56 
Process 
Efficiency 
(%) 
88.36 89.43 94.69*     
Fentanyl 
 Set #1    Set #2   
Trial no. Low Med High  Low Med High 
1 35121.93 243862.09 2277257.74  29709.08 227320.04 2041829.06 
2 36338.33 272959.43 2236877.77  29167.22 198024.25 2134377.46 
3 37012.04 266771.73 2381041.33  35764.60 218804.82 1996871.66 
Average 36157.43 261197.75 2298392.28  31546.97 214716.37 2057692.73 
Process 
Efficiency 
(%) 
87.25 82.20 89.53     
para-Methoxyfentanyl 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 27910.62 182350.93 1495982.69  22788.33 171129.57 1444155.49 
2 28307.99 187967.00 1560701.40  22972.15 154837.11 1453530.64 
3 27175.06 188179.96 1535007.01  28583.31 181306.70 1446219.28 
Average 27797.89 186165.96 1530563.70  24781.26 169091.13 1447968.47 
Process 
Efficiency 
(%) 
89.15 90.83 94.60*     
4ANPP 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 250705.82 1588320.59 10328356.33  190178.80 1229445.02 8369358.55 
2 258303.65 1581159.69 10153768.64  180041.98 1076604.71 8607365.57 
3 243397.40 1581703.72 10159658.74  202286.59 1208246.04 7867551.53 
Average 250802.29 1583728.00 10213927.90  190835.79 1171431.92 8281425.22 
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Process 
Efficiency 
(%) 
76.09 73.97 81.08*     
Furanyl Fentanyl 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 49598.48 349942.60 2901533.55  43119.60 311988.90 2601610.85 
2 53154.12 346954.45 2836640.95  42896.47 273618.10 2713430.81 
3 51906.40 357217.84 2887911.90  49315.64 319827.23 2468265.83 
Average 51553.00 351371.63 2875362.13  45110.57 301811.41 2594435.83 
Process 
Efficiency 
(%) 
87.50 85.90 90.23*     
Despropionyl para-fluorofentanyl 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 55310.89 410215.90 3346009.48  44611.95 298602.77 2379969.31 
2 59539.77 417208.83 3306663.71  42323.78 262062.45 2461242.98 
3 54462.41 429930.16 3259141.25  48160.70 302515.48 2219544.67 
Average 56437.69 419118.30 3303938.15  45032.14 287726.90 2353585.65 
Process 
Efficiency 
(%) 
79.79 68.65 71.24*     
(±)-cis-3-Methyl fentanyl 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 24054.35 166202.47 1583431.31  20491.67 156986.46 1478382.82 
2 27032.87 169935.48 1605989.18  21452.07 141056.37 1509950.96 
3 28262.03 170303.84 1617468.23  23994.77 155435.24 1401345.31 
Average 26449.75 168813.93 1602296.24  21979.50 151159.36 1463226.36 
Process 
Efficiency 
(%) 
83.10 89.54 91.32*     
Butyryl/Isobutyrl Fent 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
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1 45422.09 314101.40 2930769.08  39780.73 286850.10 2561000.97 
2 43811.81 330407.44 2863257.61  40474.67 250218.59 2732200.06 
3 43617.99 318274.99 2892301.46  41938.47 284702.64 2492138.07 
Average 44283.97 320927.94 2895442.71  40731.29 273923.77 2595113.03 
Process 
Efficiency 
(%) 
91.98 85.35 89.63*     
Carfentanil 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 29581.26 190158.75 1361256.73  20082.97 141783.79 1156826.21 
2 28035.22 185363.84 1327128.00  19522.51 125922.13 1232173.90 
3 28947.85 186650.17 1340755.27  21596.45 150266.11 1127003.16 
Average 28854.78 187390.92 1343046.67  20400.64 139324.01 1172001.09 
Process 
Efficiency 
(%) 
70.70 74.35 87.26*     
para-Fluorobutyryl/FIBF 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 54002.16 342912.34 2955695.73  40598.62 312539.77 2654829.38 
2 56611.46 339053.46 2918068.58  39133.46 276976.56 2748411.38 
3 58760.62 353647.81 2923275.93  46283.60 320551.42 2534921.27 
Average 56458.08 345204.54 2932346.74  42005.23 303355.92 2646054.01 
Process 
Efficiency 
(%) 
74.40 87.88 90.24*     
Sufentanil 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 21378.68 141092.61 1353710.93  16366.94 120199.93 1242166.50 
2 23467.13 133429.58 1365799.90  15683.01 110473.97 1269157.94 
3 21426.18 137804.06 1362923.38  19433.81 121634.57 1138826.22 
Average 22090.66 137442.08 1360811.40  17161.25 117436.15 1216716.88 
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Process 
Efficiency 
(%) 
77.69 85.44 89.41*     
Valeryl Fentanyl 
 Set #1    Set #2   
Trial no. Low Med High*  Low Med High* 
1 59939.19 373667.31 3834026.52  51047.18 370795.17 3328155.43 
2 62192.36 419395.23 3638907.11  50457.26 327512.59 3497367.43 
3 60773.11 434846.52 3925964.13  58040.14 369396.01 3238100.13 
Average 60968.22 409303.02 3799632.58  53181.53 355901.26 3354541.00 
Process 
Efficiency 
(%) 
87.23 86.95 88.29*     
*Process efficiency percentages for all IMF analogs except for fentanyl and norfentanyl were 
estimated only theoretically at the high control concentration, where the control concentration 
exceeded the calibration range. 
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